Trials / Completed
CompletedNCT02788565
Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours
SOMATOSTATIN TREATMENT EXPERIENCE TRIAL An Observational Cross Sectional Trial Investigating Quality of Life, Treatment Experience and Direct Cost of Treatment With Somatostatin Analogues in Subjects With Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 156 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Data from this study will contribute additional knowledge regarding patient outcomes and direct somatostatin analogue (SSA) treatment related costs in clinical practice in the Nordic countries. Such knowledge can be of importance in a treatment decision, decision support for development of care, follow up and training of both patients and primary care nurses.
Conditions
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2016-10-01
- Completion
- 2016-12-01
- First posted
- 2016-06-02
- Last updated
- 2020-06-02
Locations
2 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02788565. Inclusion in this directory is not an endorsement.